105 related articles for article (PubMed ID: 11943617)
1. High yield of endoreduplication induced by ICRF-193: a topoisomerase II catalytic inhibitor.
Pastor N; José Flores M; Domínguez I; Mateos S; Cortés F
Mutat Res; 2002 Apr; 516(1-2):113-20. PubMed ID: 11943617
[TBL] [Abstract][Full Text] [Related]
2. Testing the SCE mechanism with non-poisoning topoisomerase II inhibitors.
Domínguez I; Pastor N; Mateos S; Cortés F
Mutat Res; 2001 Oct; 497(1-2):71-9. PubMed ID: 11525909
[TBL] [Abstract][Full Text] [Related]
3. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
Muñoz P; Baus F; Piette J
Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells.
Pastor N; Domínguez I; Mateos S; Cortés F
Mutat Res; 2002 Mar; 515(1-2):171-80. PubMed ID: 11909765
[TBL] [Abstract][Full Text] [Related]
6. Cytogenetic effects of inhibition of topoisomerase I or II activities in the CHO mutant EM9 and its parental line AA8.
Cortés F; Piñero J; Palitti F
Mutat Res; 1993 Aug; 288(2):281-9. PubMed ID: 7688089
[TBL] [Abstract][Full Text] [Related]
7. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells.
Iwai M; Hara A; Andoh T; Ishida R
FEBS Lett; 1997 Apr; 406(3):267-70. PubMed ID: 9136899
[TBL] [Abstract][Full Text] [Related]
8. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
9. Effects of an inhibitor of topoisomerase II, ICRF-193 on the formation of ultraviolet-induced chromosomal aberrations.
Ikushima T; Shima Y; Ishii Y
Mutat Res; 1998 Aug; 404(1-2):35-8. PubMed ID: 9729258
[TBL] [Abstract][Full Text] [Related]
10. Protection of halogenated DNA from strand breakage and sister-chromatid exchange induced by the topoisomerase I inhibitor camptothecin.
Orta ML; Mateos S; Cantero G; Wolff LJ; Cortés F
Mutat Res; 2008 Jan; 637(1-2):40-8. PubMed ID: 17706727
[TBL] [Abstract][Full Text] [Related]
11. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
Nakazawa N; Arakawa O; Ebe M; Yanagida M
J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
[TBL] [Abstract][Full Text] [Related]
12. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells.
Hossain MS; Akimitsu N; Takaki T; Hirai H; Sekimizu K
Genes Cells; 2002 Mar; 7(3):285-94. PubMed ID: 11918672
[TBL] [Abstract][Full Text] [Related]
13. The high rate of endoreduplication in the repair deficient CHO mutant EM9 parallels a reduced level of methylated deoxycytidine in DNA.
Mateos S; Domínguez I; Cantero G; Pastor N; Campanella C; Cortés F
Mutat Res; 2008 Sep; 644(1-2):24-30. PubMed ID: 18640132
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events.
Ishida R; Sato M; Narita T; Utsumi KR; Nishimoto T; Morita T; Nagata H; Andoh T
J Cell Biol; 1994 Sep; 126(6):1341-51. PubMed ID: 8089169
[TBL] [Abstract][Full Text] [Related]
15. Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange.
Hamatake M; Andoh T; Ishida R
Anticancer Drugs; 1997 Jul; 8(6):637-42. PubMed ID: 9300580
[TBL] [Abstract][Full Text] [Related]
16. The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication.
Pastor N; Domínguez I; Orta ML; Campanella C; Mateos S; Cortés F
Mutat Res; 2012; 738-739():45-51. PubMed ID: 22921906
[TBL] [Abstract][Full Text] [Related]
17. A CHO-cell strain having hypersensitivity to mutagens, a defect in DNA strand-break repair, and an extraordinary baseline frequency of sister-chromatid exchange.
Thompson LH; Brookman KW; Dillehay LE; Carrano AV; Mazrimas JA; Mooney CL; Minkler JL
Mutat Res; 1982 Aug; 95(2-3):427-40. PubMed ID: 6889677
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
[TBL] [Abstract][Full Text] [Related]
19. The relationship between sister-chromatid exchange and perturbations in DNA replication in mutant EM9 and normal CHO cells.
Dillehay LE; Thompson LH; Minkler JL; Carrano AV
Mutat Res; 1983 May; 109(2):283-96. PubMed ID: 6843572
[TBL] [Abstract][Full Text] [Related]
20. Coordinated requirements of human topo II and cohesin for metaphase centromere alignment under Mad2-dependent spindle checkpoint surveillance.
Toyoda Y; Yanagida M
Mol Biol Cell; 2006 May; 17(5):2287-302. PubMed ID: 16510521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
